Literature DB >> 1479037

Audit of bone marrow trephines.

P W Bishop1, K McNally, M Harris.   

Abstract

AIMS: To establish criteria of adequacy for bone marrow trephine biopsy specimens and to audit the quality of trephines performed at the Christie Hospital, Manchester.
METHODS: Trephines (n = 767) performed over 12 months were reviewed. Their lengths, and the lengths of their constituent parts (soft tissue, cortex, crushed marrow and interpretable marrow) were measured. The mean performance of each operator was calculated. Criteria of adequacy were established by a review of the published findings and an analysis of the relation between trephine length and the rate of infiltration by tumour.
RESULTS: Before processing, the average trephine was 1.59 cm long. Trephines shrunk by 25% during processing. In histological sections the average length was 1.15 cm, consisting of 0.09 cm of soft tissue, 0.04 cm of cortex, 0.26 cm of disrupted marrow and 0.74 cm of interpretable marrow. A large number of operators were taking trephine biopsy specimens and their performance varied considerably. Review of the published findings suggested that the minimum adequate length is in the range 1.5 cm to 2.0 cm. The analysis of the relation between length of trephine and the rate of positivity for neoplasia yielded a minimum adequate length of 1.2 cm in section (1.6 cm before processing). Fifty eight per cent of the trephines were inadequate by this criterion. There was a tendency for the Jamshidi needle to produce a longer trephine than the Islam needle.
CONCLUSION: According to objective criteria, at the Christie Hospital, many operators are producing a high proportion of inadequate bone marrow trephines.

Entities:  

Mesh:

Year:  1992        PMID: 1479037      PMCID: PMC495006          DOI: 10.1136/jcp.45.12.1105

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases.

Authors:  R D Brunning; C D Bloomfield; R W McKenna; L A Peterson
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

2.  Bone marrow aspiration and trephine biopsy. An approach to a thorough study.

Authors:  R K Brynes; R W McKenna; R D Sundberg
Journal:  Am J Clin Pathol       Date:  1978-11       Impact factor: 2.493

3.  Bone marrow biopsy with unaltered architecture: a new biopsy device.

Authors:  K Jamshidi; W R Swaim
Journal:  J Lab Clin Med       Date:  1971-02

4.  A new bone marrow biopsy needle with core securing device.

Authors:  A Islam
Journal:  J Clin Pathol       Date:  1982-03       Impact factor: 3.411

  4 in total
  15 in total

1.  Trained nurses can obtain satisfactory bone marrow aspirates and trephine biopsies.

Authors:  S Lawson; S Aston; L Baker; C D Fegan; D W Milligan
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Bone marrow trephine biopsy in infants. European Neuroblastoma Study Group.

Authors:  M M Reid; B Roald
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

3.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

4.  Adequacy of bone marrow trephine biopsy specimens in children.

Authors:  M M Reid; B Roald
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

5.  Bone marrow trephine biopsy.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

Review 6.  A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination.

Authors:  Roger S Riley; Thomas F Hogan; Dawn R Pavot; Robert Forysthe; Davis Massey; Eileen Smith; Lou Wright; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

7.  Using a powered bone marrow biopsy system results in shorter procedures, causes less residual pain to adult patients, and yields larger specimens.

Authors:  James R Berenson; Ori Yellin; Brent Blumenstein; Deanna Bojanower; Jonathan Croopnick; David Aboulafia; Gargi Upadhyaya; Cathy Spadaccini
Journal:  Diagn Pathol       Date:  2011-03-23       Impact factor: 2.644

8.  The OnControl bone marrow biopsy technique is superior to the standard manual technique for hematologists-in-training: a prospective, randomized comparison.

Authors:  Louis Juden Reed; Radha Raghupathy; Marianna Strakhan; Thomas E Philbeck; Mimi Y Kim; Ramakrishna Battini; Zulfiqar Hussain; Shaad Abdullah; Sarah Schweber; Kamalesh Bala; Thomas Pacello
Journal:  Hematol Rep       Date:  2011-10-25

9.  Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices.

Authors:  Larry J Miller; Thomas E Philbeck; Diana F Montez; Tatiana A Puga; Kim E Brodie; Stephen C Cohen; Cathy Spadaccini; Ronan Swords; Andrew J Brenner
Journal:  Hematol Rep       Date:  2011-06-18

10.  Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Authors:  Mihai Merzianu; Adrienne Groman; Alan Hutson; Claudiu Cotta; Russell K Brynes; Attilio Orazi; Vishnu Reddy; Julie Teruya-Feldstein; Ramila Amre; Manjula Balasubramanian; Guilherme Brandao; Sindhu Cherian; Elizabeth Courville; David Czuchlewski; Guang Fan; David Grier; Daniela Hoehn; Kedar V Inamdar; Ridas Juskevicius; Prabhjot Kaur; John Lazarchick; Michael R Lewis; Rodney R Miles; Jerome B Myers; Michel R Nasr; Hina N Qureishi; Horatiu Olteanu; Valentin G Robu; Gratian Salaru; Neerja Vajpayee; Jeffrey Vos; Ling Zhang; Shanxiang Zhang; Le Aye; Elisa Brega; James E Coad; John Grantham; Sinisa Ivelja; Robert McKenna; Kieran Sultan; Gregory Wilding; Robert Hutchison; LoAnn Peterson; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2018-10-01       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.